Xencor
Pre-Approval PRO BETAPipeline by Phase
Therapeutic Focus
Clinical Trials (27)
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Started: 10/22/2021
A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
Started: 7/21/2022
Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)
Started: 4/15/2022
A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus
Started: 2/16/2016
Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD)
Started: 3/1/2016
A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid Arthritis
Started: 10/21/2025
Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
Started: 10/10/2024
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Started: 4/4/2024
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Started: 6/13/2022
Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC
Started: 12/27/2023
A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Idiopathic Inflammatory Myopathy (IIM)
Started: 2/1/2026
Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis
Started: 10/10/2022
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
Started: 12/14/2022
Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies
Started: 10/1/2016
A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors
Started: 7/28/2023
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
Started: 5/1/2019
Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer
Started: 5/10/2021
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
Started: 5/29/2019
Study Evaluating AMG 424 in Subjects With Multiple Myeloma
Started: 7/31/2018
Safety, Tolerability and PK of a Single Subcutaneous Injection of XmAb27564 in Healthy Volunteers
Started: 4/19/2021
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
Started: 7/10/2018
A Study of XmAb®18087 in Subjects With NET and GIST
Started: 1/22/2018
PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies
Started: 8/1/2016
Safety, Tolerability, and Bioavailability of Subcutaneously Administered XmAb®7195
Started: 8/17/2016
Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis
Started: 5/1/2014
Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia
Started: 9/1/2010